PI3 kinase inhibitors in the clinic: an update
- PMID: 22753702
PI3 kinase inhibitors in the clinic: an update
Abstract
The phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway has been identified as a key signaling pathway for important cellular functions such as growth control, metabolism and translation initiation. Several proteins within this pathway are valuable anticancer drug targets, among which several inhibitors of mTOR are now administered in routine practice. A better understanding of the structure and functions of PI3K has led to the development of novel inhibitors that have a more favorable toxicity profile as compared to the first generation of anti-PI3K drugs. In this article, we review the basics of PI3K biology and focus on its inhibitors, currently under investigation in clinical trials. The perspective for future directions in the setting of PI3K inhibition and novel trials is also discussed.
Similar articles
-
Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.Cancer Res. 2005 Sep 1;65(17):7800-8. doi: 10.1158/0008-5472.CAN-04-4180. Cancer Res. 2005. PMID: 16140948
-
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.Oncologist. 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12. Oncologist. 2011. PMID: 21278436 Review.
-
New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.Clin Cancer Res. 2013 Oct 1;19(19):5264-74. doi: 10.1158/1078-0432.CCR-13-0615. Clin Cancer Res. 2013. PMID: 24089439 Review.
-
Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.Bioorg Med Chem Lett. 2012 Sep 1;22(17):5445-50. doi: 10.1016/j.bmcl.2012.07.042. Epub 2012 Jul 17. Bioorg Med Chem Lett. 2012. PMID: 22863202
-
Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.Bioorg Med Chem Lett. 2010 Apr 15;20(8):2586-90. doi: 10.1016/j.bmcl.2010.02.082. Epub 2010 Feb 23. Bioorg Med Chem Lett. 2010. PMID: 20303263
Cited by
-
PTEN in cancer, metabolism, and aging.Trends Endocrinol Metab. 2013 Apr;24(4):184-9. doi: 10.1016/j.tem.2012.11.002. Epub 2012 Dec 12. Trends Endocrinol Metab. 2013. PMID: 23245767 Free PMC article. Review.
-
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.Mol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27. Mol Cancer Ther. 2013. PMID: 23270925 Free PMC article.
-
Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments.Mol Neurobiol. 2019 Jun;56(6):4492-4517. doi: 10.1007/s12035-018-1390-4. Epub 2018 Oct 18. Mol Neurobiol. 2019. PMID: 30338483 Free PMC article.
-
Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.Leukemia. 2013 Dec;27(12):2397-403. doi: 10.1038/leu.2013.150. Epub 2013 May 14. Leukemia. 2013. PMID: 23670295 Free PMC article. No abstract available.
-
A comprehensive review of protein kinase inhibitors for cancer therapy.Expert Rev Anticancer Ther. 2018 Dec;18(12):1249-1270. doi: 10.1080/14737140.2018.1527688. Epub 2018 Oct 9. Expert Rev Anticancer Ther. 2018. PMID: 30259761 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
